iRGD-CPT

• UNSPSC Description:

  iRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer[1].

• Target Antigen:

  DNA/RNA Synthesis; Integrin; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/irgd-cpt.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(CC1SC[C@H](NC(C)=O)C(N[C@@H]2C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(NCC(N3CCC[C@H]3C(N[C@H](C(N[C@@H](CSSC2)C(O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N(CCC(NOCCOCCOCCCC(O[C@]4(CC)C(OCC5=C4C=C6N(CC7=CC8=CC=CC=C8N=C76)C5=O)=O)=O)=O)C1=O

• Molecular Weight:

  1781.90

• References & Citations:

  [1]Singh, Tejinder et al. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy. European journal of medicinal chemistry, vol. 265 116050. 16 Dec. 2023

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported